Loading...

DBVT DBV TECHNOLOGIES SA US FDA Inspections 8-K Filing

DBV

DBVT

DBV TECHNOLOGIES SA

(DBVT)

2023 8-K

Show Summary

Summary

New Product Launches

Compensatory Arrangements o...

Financial Statements

Private Placement

Financial Results

Positive Study Results

Management Changes

Nasdaq Compliance

FDA Approval Pathway

ADS Ratio Change

Financial Results

Financial Update

Clinical Trial Update

Earnings Report

Ratio Change Announcement

Ratio Change of ADSs

Amendments to Bylaws and Sh...

Earnings Report

Financial Results and Busin...

Appointment of CFO

Amendment to Form 8-K/A

Termination of Agreement

Appointment of CFO and Depa...

Earnings Report

Publication of Phase 3 EPIT...

Earnings Report

Financial Condition and Oth...

Annual General Meeting

Regulation FD Disclosure

Clinical Trial Announcement

Financial Results Announcement

External Links:

DBV Technologies S.A. had $192.3 million of cash and cash equivalents as of March 31, 2023. The company announced the regulatory path for investigational Viaskin Peanut 250 g patch in toddlers with peanut allergy.

AI Assistant

DBV TECHNOLOGIES SA

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.